Physician profile
Bryan S Poe
NPI 1093888380
$1,398.74
in general payments reported to CMS, 2019-2025
19 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.35 · 2020: $274 · 2021: $205 · 2022: $158 · 2023: $121 · 2024: $208 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $272.93 | 2019-2024 | |
| Lilly USA, LLC | $235.97 | 2020-2025 | Mounjaro |
| Abbott Laboratories | $197.29 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $96.26 | 2020-2025 | Breztri |
| Xeris Pharmaceuticals, INC. | $83.86 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $83.15 | 2019-2022 | |
| Amarin Pharma, INC. | $73.77 | 2019-2021 | |
| Astellas Pharma US INC | $69.81 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $45.53 | 2023-2025 | Superion Indirect Decompression System, Watchman Access System |
| Novo Nordisk INC | $44.07 | 2024-2025 | Rybelsus |
| Abbvie INC. | $33.00 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.10 | 2021 | |
| Insulet Corporation | $26.31 | 2025 | Omnipod |
| Amgen INC. | $23.45 | 2023 | Otezla, Repatha |
| Eisai INC. | $22.73 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.72 | 2021 | |
| Tactile Systems Technology INC | $14.88 | 2024 | Entre Plus, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Poe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.